銵?鋆蔭?詨
ABOUT US PIPELINE
LBS-008
LBS-009
LBS-007
LBS-002
MEDIA & PUBLICATION
NEWS
PUBLICATION
INVESTORS
Events & Presentation
Investor Conference
Financial Information
Corporate Governance
CONTACT US
MEDIA & PUBLICATION
HOMEMEDIA & PUBLICATIONNEWS
NEWS
PUBLICATION
NEWS
Belite Bio Announces Start of LBS-008 Phase 3 Stargardt Disease Trial
Jul 09 , 2021
Lin BioScience raises $30 million in its rights issue to support LBS-008’s phase 3 clinical trial to treat Stargardt disease
Sep 16 , 2020
Belite Bio Announces FDA Approval of Investigational New Drug (IND) for Phase 1 Clinical Trial of LBS-008 to Treat Macular Degeneration and Stargardt Disease
Apr 24 , 2019
Belite Bio Initiates Phase 1 Study of LBS-008 in Australia
Oct 02 , 2018
FDA Grants Lin BioScience Rare Pediatric Disease Status for LBS-008 to Treat Stargardt Disease
Sep 18 , 2018